Advertisement
Advertisement
ENGN
enGene Holdings Inc. Common Stock
6.83
USDSponsored
-0.13
-1.84%
Mar 27, 09:32 UTC -4
Open
ENGN Earnings Reports
Positive Surprise Ratio
ENGN beat 3 of 8 last estimates.
38%
Next Report
Date of Next Report
Jun 01, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.48
Implied change from Q1 26 (Revenue/ EPS)
--
/+9.09%
Implied change from Q2 25 (Revenue/ EPS)
--
/-5.88%
enGene Holdings Inc. Common Stock earnings per share and revenue
On Mar 09, 2026, ENGN reported earnings of -0.44 USD per share (EPS) for Q1 26, beating the estimate of -0.57 USD, resulting in a 22.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -18.78% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.48 USD, with revenue projected to reach -- USD, implying an increase of 9.09% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were enGene Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, enGene Holdings Inc. Common Stock reported EPS of -$0.44, beating estimates by 22.94%, and revenue of $0.00, 0% as expectations.
How did the market react to enGene Holdings Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -18.78%, changed from $8.68 before the earnings release to $7.05 the day after.
When is enGene Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for Jun 01, 2026.
What are the forecasts for enGene Holdings Inc. Common Stock's next earnings report?
Based on 11
analysts, enGene Holdings Inc. Common Stock is expected to report EPS of -$0.48 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement